TrialThe oncologist2026

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Jean-Jacques Kiladjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.